Theriva Biologics (TOVX) Stock: Buy, Sell, or Hold?
TOVX - Theriva Biologics, Inc.
$0.19
0.00 (-2.49%)
▼
5d:
-9.58%
30d:
-18.32%
90d:
-14.0%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 11, 2026
19d
Get Alerted When TOVX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: TOVX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: TOVX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: TOVX is currently trading at $0.19, which is considered oversold relative to its 30-day fair value range of $0.21 to $0.23.
Technical Outlook: Technically, TOVX is in a downtrend. The price is currently testing key support at $0.20. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TOVX scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.50 (+1171.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TOVX is in a downtrend. The price is currently testing key support at $0.20. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TOVX scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.50 (+1171.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.21 -
$0.23
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1171.6% below Wall St target ($2.50)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.21 -
$0.23
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.20
Resistance Level
$0.24
Current Trend
Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.98
Wall Street Target
$2.50
(+1171.6%)
Share & Embed Analysis
Last updated: October 22, 2026 11:25 AM ET
Data refreshes hourly during market hours. Next update: 12:25 PM
Data refreshes hourly during market hours. Next update: 12:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TOVX showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 50 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$75 | 70 BUY |
|
KURA
Kura Oncology Inc |
STRONG BUY
16 analysts |
$32 | 62 BUY |